Ivosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH1-Mutated AML or MDS/AML Considered Ineligible for Intensive Chemotherapy

NCT07075016 · clinicaltrials.gov ↗
PHASE3
Phase
RECRUITING
Status
227
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Stichting Hemato-Oncologie voor Volwassenen Nederland

Collaborators